ertapenem
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Continuous Ambulatory Peritoneal Dialysis
Conditions
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Trial Timeline
Jun 1, 2009 → May 1, 2010
NCT ID
NCT00939952About ertapenem
ertapenem is a approved stage product being developed by Merck for Continuous Ambulatory Peritoneal Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT00939952. Target conditions include Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02041767 | Approved | Completed |
| NCT01159379 | Approved | UNKNOWN |
| NCT01203046 | Phase 2/3 | Completed |
| NCT01173068 | Pre-clinical | UNKNOWN |
| NCT00939952 | Approved | Completed |
Competing Products
2 competing products in Continuous Ambulatory Peritoneal Dialysis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dexmedetomidine + Propofol | Orion Corporation | Phase 3 | 74 |
| Dexmedetomidine + Midazolam | Orion Corporation | Phase 3 | 74 |